Skip to main content
Clinical Trials/NCT05916443
NCT05916443
Not yet recruiting
Not Applicable

Study of the Biology of Colorectal Cancer in Early-onset Patients

Fondazione Policlinico Universitario Agostino Gemelli IRCCS0 sites30 target enrollmentAugust 1, 2023
ConditionsColon Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Colon Cancer
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment
30
Primary Endpoint
Isolation and characterization of EO-CRC-derived CSCs
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Contrarily to late-onset (LO) colorectal cancer (CRC), early-onset (EO) CRC incidence is increasingly growing. Several factors, such as obesity, chronic inflammation, and intestinal dysbiosis, can increase the general risk of CRC. However, little is known about the biology of EO-CRC. To evaluate whether such selective rise in the incidence of EO-CRC patients mirrors a distinct transcriptomic profile, the investigators will first dissect EO-CRC's transcriptomic landscape.

Then, the investigators will investigate the colorectal cancer stem cell (CSC) compartment by in vitro functional assays and RNA-seq analysis. Because our preliminary data indicate an increased aggressiveness of the tumor microenvironment (TME) in EO-CRC,the investigators propose to investigate the CSC niche and the interaction with the TME to dissect the molecular and cellular pathways occurring in EO-CRC.

A cohort of 30 EO-CRC patients (<50 years old) will be enrolled and fully characterized. About 10 EO-CRC-derived CSCs in the form of organoids and spheroids will be generated. Since the relevant differences between CR-CSCs isolated from EO-CRC vs LO-CRC patients are still unknown, the investigators will gain information about their specific features such as clonogenic activity, tumorigenic/invasive capacity, and about differences in the mechanisms regulating their cross-talk with TME components.

Registry
clinicaltrials.gov
Start Date
August 1, 2023
End Date
September 30, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • age \> 18 and \< 50 years ;
  • Written informed consent

Exclusion Criteria

  • Non-availability of informed consent.

Outcomes

Primary Outcomes

Isolation and characterization of EO-CRC-derived CSCs

Time Frame: 2 years

Identification of EO-CRC-derived CSCs by cytofluorimetry and immunofluorescence analyses (Percentage of cells positive for CD133, CD24, CD44 and CD44v6 expression).

Identification of EO-CRC specific signatures and pathways

Time Frame: 2 years

RNAseq data analysis of differentially expressed genes in EO-CRC-derived CSCs compared with LO-CRC-derived CSCs.

Identification of obesity-associated adipokines in EO-CRC obese patients

Time Frame: 2 years

Elisa/Luminex assay evaluation of obesity-associated adipokines concentration

Similar Trials